Drawing for POLYNAUT

USPTO serial 99630692

POLYNAUT

Reviewed by CopyMark Law Group

Status 653
Filing date
Status date
Registration date
—
Examiner
FLOWERS, JAY K
Law office
TMO LAW OFFICE 112

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with POLYNAUT?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Ben Natter

Ben Natter Haug Partners, LLP745 Fifth AvenueNew York, NY 10151United States

Goods and services

ClassDescriptionStatusFirst use
001Chemicals used in science; chemicals for encapsulating, microencapsulating and decapsulating other chemicals; chemicals for the protection, delivery, transport and triggered or controlled release of other chemicals; chemicals for encapsulating, microencapsulating and decapsulating biologically active ingredients including enzymes and cells; reagents and diagnostic preparations for scientific or medical research use, and clinical or medical laboratory use; targeted diagnostic preparations for scientific or medical research use, and clinical or medical laboratory useACTIVE—
005Pharmaceutical preparations; Pharmaceutical preparations for the treatment and prevention of infectious, autoimmune, viral, metabolic, musculoskeletal, cardiovascular, genitourinary, central nervous system, endocrinological, immunological, obstetrical, gynaecological, oncological, respiratory, neurological, gastrointestinal, hormonal, dermatological and psychiatric diseases and disorders; reagents, diagnostics, prophylactics and therapeutic preparations for use in conditions of the central and peripheral nervous systems, immune system and diseases of the lung, kidney, liver or any peripheral organs, and oncology; vaccines; therapeutic preparations for use in treating diseases of the central and peripheral nervous systems, immune system and diseases of lung, kidney, liver or other organs, and cancer in medical and veterinary patients; targeted preparations for treating diseases of the central and peripheral nervous systems, immune system and diseases of lung, kidney, liver or other organs, or cancer; medical and veterinary preparations for use in for use in central and peripheral nervous system diseases, immune system, diseases, diseases of the lung, kidney, liver and other organs, and cancer; medical and veterinary preparations for the delivery of compounds to the brain for the treatment and prevention of infectious, autoimmune, viral, metabolic, musculoskeletal, cardiovascular, genitourinary, central nervous system, endocrinological, immunological, obstetrical, gynaecological, oncological, respiratory, neurological, gastrointestinal, hormonal, dermatological and psychiatric diseases and disorders; medical and veterinary preparations for crossing the blood-brain barrier for the treatment and prevention of infectious, autoimmune, viral, metabolic, musculoskeletal, cardiovascular, genitourinary, central nervous system, endocrinological, immunological, obstetrical, gynaecological, oncological, respiratory, neurological, gastrointestinal, hormonal, dermatological and psychiatric diseases and disorders; medical and veterinary preparations for delivering reagents, diagnostics, prophylactics and therapeutics across the blood-brain barrier for the treatment and prevention of infectious, autoimmune, viral, metabolic, musculoskeletal, cardiovascular, genitourinary, central nervous system, endocrinological, immunological, obstetrical, gynaecological, oncological, respiratory, neurological, gastrointestinal, hormonal, dermatological and psychiatric diseases and disordersACTIVE—
042Scientific and technological services, namely, scientific research, analysis, testing and development in the field of delivering therapeutics, drug delivery technologies and medicines and research and design relating thereto; industrial analysis and research services in the field of therapeutics, drug delivery technologies and medicines; research and development in the field of encapsulating, microencapsulating and decapsulating chemicals and biologicals for delivery into human or animal cells; medical and veterinary research services; scientific research in the development of new therapies and new methods for delivering therapies; scientific research into nanoparticles; scientific research into encapsulation, microencapsulation and de-capsulation of reagents, diagnostics, prophylactics and therapeutics; scientific research into crossing the blood brain barrier and other biological barriers; scientific research into nano-engineering for intracellular delivery; platform as a service (PAAS) featuring computer software platforms for developing drug delivery products to deliver genetic materials with precise targeting of specific tissues and cell types; platform as a service (PAAS) featuring computer software platforms for research and development of genetic medicine delivery; consultancy relating to all the aforesaid services.ACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 21, 2026GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Aug 21, 2026GNSLLETTER OF SUSPENSION E-MAILED—
Aug 21, 2026CNSLSUSPENSION LETTER WRITTEN—
Aug 20, 2026TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Aug 20, 2026CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 20, 2026TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 5, 2026GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 5, 2026GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 5, 2026CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 1, 2026DOCKASSIGNED TO EXAMINER—
May 28, 2026NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 3, 2026MAFRAPPLICATION FILING RECEIPT MAILED—
Feb 3, 2026NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance